Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model
暂无分享,去创建一个
S. Hankinson | L. Brinton | T. Key | Mengling Liu | A. Swerdlow | M. Schoemaker | G. Hallmans | P. Sluss | V. Krogh | A. Zeleniuch‐Jacquotte | D. Sandler | R. Falk | F. Darvishian | Y. Afanasyeva | K. Koenig | C. Agnoli | H. Nichols | K. Visvanathan | A. Eliassen | T. Clendenen | J. Hoffman-Bolton | M. Sund | Wenzhen Ge | J. Dorgan | Judith A. Hoffman-Bolton
[1] W. H. Pearse. American College of Obstetricians and Gynecologists , 2020, Definitions.
[2] Vittorio Krogh,et al. Circulating anti‐Müllerian hormone and breast cancer risk: A study in ten prospective cohorts , 2018, International journal of cancer.
[3] A. Tjønneland,et al. Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women. , 2017, Fertility and sterility.
[4] A. Fournier,et al. Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort , 2017, Clinical Cancer Research.
[5] M. Eijkemans,et al. Back to the basics of ovarian aging: a population-based study on longitudinal anti-Müllerian hormone decline , 2016, BMC Medicine.
[6] B. Rosner,et al. Plasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[7] T. Wilt,et al. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.
[8] G. Giles,et al. Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[9] C. Kooperberg,et al. SNPs and breast cancer risk prediction for African American and Hispanic women , 2015, Breast Cancer Research and Treatment.
[10] J. Lortet-Tieulent,et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. , 2015, JAMA.
[11] A. Pinborg,et al. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. , 2015, Human reproduction.
[12] Charmaine Pei Ling Lee,et al. Mammographic Breast Density and Common Genetic Variants in Breast Cancer Risk Prediction , 2015, PloS one.
[13] M. Gail. Twenty-five years of breast cancer risk models and their applications. , 2015, Journal of the National Cancer Institute.
[14] D. Baird,et al. Anti-Müllerian Hormone Concentrations in Premenopausal Women and Breast Cancer Risk , 2015, Cancer Prevention Research.
[15] Stefan Michiels,et al. A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort , 2015, Breast Cancer Research and Treatment.
[16] M. García-Closas,et al. Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. , 2014, Journal of the National Cancer Institute.
[17] Peter Kraft,et al. Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] F. Clavel-Chapelon,et al. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status—Results from the EPIC cohort , 2014, International journal of cancer.
[19] A. Ashworth,et al. Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study , 2014, British Journal of Cancer.
[20] F. Berrino,et al. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. , 2013, The Lancet. Oncology.
[21] J. Cuzick,et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Hartge,et al. Risk Prediction for Breast, Endometrial, and Ovarian Cancer in White Women Aged 50 y or Older: Derivation and Validation from Population-Based Cohort Studies , 2013, PLoS medicine.
[23] G. Giles,et al. Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model , 2013, Breast Cancer Research and Treatment.
[24] Anne Marie McCarthy,et al. Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women , 2013, Breast Cancer Research and Treatment.
[25] W. Willett,et al. Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II , 2013, Breast Cancer Research.
[26] Xuehong Zhang,et al. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up , 2013, Breast Cancer Research and Treatment.
[27] Peter Kraft,et al. Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status , 2012, Journal of Medical Genetics.
[28] E. Papaleo,et al. Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history. , 2012, European journal of obstetrics, gynecology, and reproductive biology.
[29] Patrik Magnusson,et al. American Journal of Epidemiology Practice of Epidemiology Risk Prediction Measures for Case-cohort and Nested Case-control Designs: an Application to Cardiovascular Disease , 2022 .
[30] L. Hauk. American College of Obstetricians and Gynecologists Updates Breast Cancer Screening Guidelines , 2012 .
[31] Ammarin Thakkinstian,et al. Risk prediction models of breast cancer: a systematic review of model performances , 2012, Breast Cancer Research and Treatment.
[32] Mengling Liu,et al. Premenopausal serum androgens and breast cancer risk: a nested case-control study , 2012, Breast Cancer Research.
[33] Jianjun Liu,et al. Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement , 2011, Breast Cancer Research.
[34] L. Brinton,et al. Serum antimüllerian hormone in healthy premenopausal women. , 2011, Fertility and sterility.
[35] Mitchell H Gail,et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. , 2011, Journal of the National Cancer Institute.
[36] J. Manson,et al. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. , 2011, Journal of the National Cancer Institute.
[37] Practice bulletin no. 122: Breast cancer screening. , 2011, Obstetrics and gynecology.
[38] L. Brinton,et al. Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk , 2010, Breast Cancer Research.
[39] David A. Hinds,et al. Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information , 2010, Journal of the National Cancer Institute.
[40] L. Brinton,et al. Assay reproducibility and within-person variation of Müllerian inhibiting substance. , 2010, Fertility and sterility.
[41] P. Hartge,et al. Effect of changing breast cancer incidence rates on the calibration of the Gail model. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] M. Thun,et al. Performance of Common Genetic Variants in Breast-cancer Risk Models , 2022 .
[43] D. Saslow,et al. Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening , 2010, CA: a cancer journal for clinicians.
[44] D. English,et al. Circulating Steroid Hormone Levels and Risk of Breast Cancer for Postmenopausal Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[45] Timothy J Wilt,et al. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.
[46] L. Brinton,et al. Prospective Case–Control Study of Serum Müllerian Inhibiting Substance and Breast Cancer Risk , 2009, Journal of the National Cancer Institute.
[47] D. Schopper,et al. How effective are breast cancer screening programmes by mammography? Review of the current evidence. , 2009, European journal of cancer.
[48] J. Cuzick,et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] F. Berrino,et al. Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort , 2009, Cancer Epidemiology Biomarkers & Prevention.
[50] R. Vierkant,et al. Assessment of the accuracy of the Gail model in women with atypical hyperplasia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] M. Gail. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. , 2008, Journal of the National Cancer Institute.
[52] Karla Kerlikowske,et al. Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model , 2008, Annals of Internal Medicine.
[53] Melissa Bondy,et al. Projecting individualized absolute invasive breast cancer risk in African American women. , 2007, Journal of the National Cancer Institute.
[54] G. Anderson,et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. , 2007, Journal of the National Cancer Institute.
[55] C. Klabunde,et al. Evaluating Population-Based Screening Mammography Programs Internationally. , 2007, Seminars in breast disease.
[56] Stefano Calza,et al. Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. , 2006, Journal of the National Cancer Institute.
[57] D. Spiegelman,et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. , 2006, Journal of the National Cancer Institute.
[58] S. Reis,et al. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial , 2006 .
[59] Karla Kerlikowske,et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. , 2006, Journal of the National Cancer Institute.
[60] Jinbo Chen,et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. , 2006, Journal of the National Cancer Institute.
[61] Norman Wolmark,et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.
[62] D. Spiegelman,et al. Reproducibility of Plasma Steroid Hormones, Prolactin, and Insulin-like Growth Factor Levels among Premenopausal Women over a 2- to 3-Year Period , 2006, Cancer Epidemiology Biomarkers & Prevention.
[63] J. Chang-Claude,et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. , 2005, Endocrine-related cancer.
[64] S. Cummings,et al. Mammographic Breast Density and the Gail Model for Breast Cancer Risk Prediction in a Screening Population , 2005, Breast Cancer Research and Treatment.
[65] J. Chang-Claude,et al. Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2005 .
[66] J. Habbema,et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. , 2005, Fertility and sterility.
[67] F. Berrino,et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women , 2004, International journal of cancer.
[68] F. Berrino,et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. , 2004, European journal of endocrinology.
[69] R. Shore,et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study , 2004, British Journal of Cancer.
[70] G. Berglund,et al. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden) , 2003, Cancer Causes & Control.
[71] Sowmya R. Rao,et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. , 2003, Journal of the National Cancer Institute.
[72] A. Oshima,et al. Estimation of individualized probabilities of developing breast cancer for Japanese women , 2003, Breast cancer.
[73] T. Key,et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.
[74] D Spiegelman,et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.
[75] K. Hughes,et al. The Effectiveness of the Gail Model in Estimating Risk for Development of Breast Cancer in Women Under 40 Years of Age , 2001, The breast journal.
[76] M H Gail,et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.
[77] J Benichou,et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.
[78] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[79] Sven Ove Samuelsen,et al. A psudolikelihood approach to analysis of nested case-control studies , 1997 .
[80] M. Dowsett,et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. , 1997, British Journal of Cancer.
[81] M. Dowsett,et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. , 1997, British Journal of Cancer.
[82] C. D. Atkins. Re: Validation of the Gail et al. model for predicting individual breast cancer risk. , 1994, Journal of the National Cancer Institute.
[83] G. Colditz,et al. COMMENT ON : VALIDATION OF THE GAIL ET AL. MODEL FOR PREDICTING INDIVIDUALBREAST CANCER RISK. AUTHORS' REPLY , 1994 .
[84] Re: Validation of the Gail et al. model for predicting individual breast cancer risk. , 1994, Journal of the National Cancer Institute.
[85] D P Byar,et al. Estimating the population attributable risk for multiple risk factors using case-control data. , 1985, American journal of epidemiology.